Rapid Pathogen Screening, Inc. (RPS) is a biotechnology company focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. RPS products are developed using a patented technology platform which the company can utilize to develop a variety of cost-effective tests. RPS tests allow healthcare providers to more accurately diagnose diseases, provide appropriate and timely treatment, and reduce healthcare costs associated with spread of disease and unnecessary treatment methods. As of 2014, RPS has two tests approved for use in the United States with an additional test approved in the EU.
